



Foto: Christoph Soeder / Deutsches
Zentrum für Altersfragen

Die Nationale Demenzstrategie



UNIVERSITÄT
LEIPZIG

Medizinische Fakultät



Die AgeWell.de-Studie

Ein Demenzpräventionstrial unter COVID19- Pandemiebedingungen

Prof. Dr. med. Steffi G. Riedel-Heller, MPH


PD Dr. Melanie Lupp, Dr. Susanne Röhr

&


die AgeWell.de-Studienzentrenleiter

Vom Risikofaktor zum Präventionsprogramm


Wissen zu Risikofaktoren



Einzelne Interventionsstudien



Multi-Komponenten-Interventionen



Vorreiter: FINGER-Studie Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (Ngandu et al., 2015)



AgeWell-Studie – eine Multikomponentenintervention (c-RCT) für Risikopersonen

Wer?


60-77jährige
Allgemeinarztpatienten
Risikogruppe (CAIDE-Score)



Was?



Stand?



Zülke A, Luck T, Pabst A, Hoffmann W, Thyrian JR, Gensichen J, Kaduszkiewicz H, König HH, Haefeli WE, Czock D, Wiese B, Frese T, Röhr S, Riedel-Heller SG. AgeWell.de - study protocol of a pragmatic multi-center cluster-randomized controlled prevention trial against cognitive decline in older primary care patients. BMC Geriatr. 2019 Aug 1;19(1):203. doi: 10.1186/s12877-019-1212-1.



Die deutsche AgeWell-Studie: Aktueller Stand

StudienteilnehmerInnen (n = 1030)

Alter, M (SD)	69.0 (4.9)
Geschlecht, weiblich %	52.1%
Bildung, niedrig, mittel, hoch, %	24.4, 53.0, 22.6
Kog. Leistung (MoCA), M	24.5
Kog. Leistung (MoCA), ≥ 26 , %	39.4%
Demenzrisiko (CAIDE), M (SD)	10.2
Interventionsgruppe, %	47.3%



Article

Recruitment and Baseline Characteristics of Participants in the AgeWell.de Study—A Pragmatic Cluster-Randomized Controlled Lifestyle Trial against Cognitive Decline

Susanne Röhr^{1,2,*,†}, Andrea Zülke^{1,†}, Melanie Luppä¹, Christian Brettschneider³, Marina Weissenborn⁴, Flora Kühne⁵, Isabel Zöllinger⁵, Franziska-Antonia Zora Samos⁶, Alexander Bauer⁶, Juliane Döhring⁷, Kerstin Krebs-Hein⁷, Anke Oey⁸, David Czock⁴, Thomas Frese⁶, Jochen Gensichen⁵, Walter E. Haefeli⁴, Wolfgang Hoffmann^{9,10}, Hanna Kaduszkiewicz⁷, Hans-Helmut König³, Jochen René Thyrian^{9,10}, Birgitt Wiese⁸ and Steffi G. Riedel-Heller¹

- ¹ Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty University of Leipzig, 04103 Leipzig, Germany; andrea.zuelke@medizin.uni-leipzig.de (A.Z.); melanie.luppae@medizin.uni-leipzig.de (M.L.); Steffi.Riedel-Heller@medizin.uni-leipzig.de (S.G.R.-H.)
 - ² Global Brain Health Institute (GBHI), Trinity College Dublin, D02 PN40 Dublin, Ireland
 - ³ Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; c.brettschneider@uke.de (C.B.); h.koenig@uke.de (H.-H.K.)
 - ⁴ Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, 69120 Heidelberg, Germany; marina.weissenborn@med.uni-heidelberg.de (M.W.); david.czock@med.uni-heidelberg.de (D.C.); walter.emil.haefeli@med.uni-heidelberg.de (W.E.H.)
 - ⁵ Institute of General Practice/Family Medicine, University Hospital of LMU Munich, 80336 Munich, Germany; flora.kuehne@med.uni-muenchen.de (F.K.); isabel.zoellinger@med.uni-muenchen.de (I.Z.); jochen.gensichen@med.uni-muenchen.de (J.G.)
 - ⁶ Institute of General Practice and Family Medicine, Martin-Luther-University Halle-Wittenberg, 06112 Halle (Saale), Germany; franziska.samos@medizin.uni-halle.de (F.-A.Z.S.); alexander.bauer@medizin.uni-halle.de (A.B.); thomas.frese@uke-halle.de (T.F.)
 - ⁷ Institute of General Practice, University of Kiel, 24105 Kiel, Germany; j.doehring@allgemeinmedizin.uni-kiel.de (J.D.); kkh@allgemeinmedizin.uni-kiel.de (K.K.-H.); kaduszkiewicz@allgemeinmedizin.uni-kiel.de (H.K.)
 - ⁸ Institute for General Practice, Work Group Medical Statistics and IT-Infrastructure, Hannover Medical School, 30625 Hannover, Germany; oey.anke@mh-hannover.de (A.O.); wiese.birgitt@mh-hannover.de (B.W.)
 - ⁹ Institute for Community Medicine, University Medicine Greifswald, 17489 Greifswald, Germany; wolfgang.hoffmann@uni-greifswald.de (W.H.); jochen.thyrian@dzne.de (J.R.T.)
 - ¹⁰ German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, 17489 Greifswald, Germany
- * Correspondence: susanne.roehr@medizin.uni-leipzig.de; tele: +49-341-9724568; fax: +49-341-9724569
† These two authors contributed equally.



Citation: Röhr, S.; Zülke, A.; Luppä, M.; Brettschneider, C.; Weissenborn, M.; Kühne, F.; Zöllinger, I.; Samos, F.A.-A.; Bauer, A.; Döhring, J.; et al. Recruitment and Baseline Characteristics of Participants in the AgeWell.de Study—A Pragmatic Cluster-Randomized Controlled Lifestyle Trial against Cognitive Decline. *Int. J. Environ. Res. Public Health* **2021**, *18*, 408. <https://doi.org/10.3390/ijerph18020408>

Received: 25 November 2020




Die deutsche AgeWell-Studie: Timeline

Baseline:
08/2018-11/2019

Lockdown

- Interventionsperiode -

Nachbefragung:
08/2020-11/2021





COVID-19-Pandemie: Impact auf AgeWell-Studie

1. Infektionsschutzmaßnahmen - insbesondere der Lockdown schränken **interventionsrelevante Lebensstilbereiche** ein (v.a. körperliche und soziale Aktivität, psychisches Wohlbefinden)
2. Hohes **Infektionsgeschehen lässt keine persönlichen Interviews im Rahmen der 2-Jahre-Nachbefragung zu** (Endpunkt des Trials) – Assessments müssen pausieren – Verlängerung zwingend



COVID-19-Pandemie: Aktuelles Vorgehen und Maßnahmen in AgeWell.de

1. Zusätzliches **postalisches Survey** mit allen Studienteilnehmern im 1. und 2. Lockdown:
 - Veränderungen und wahrgenommene Einschränkungen im Alltag
 - Einstellungen zu COVID-19 und Infektionsschutzmaßnahmen
 - Soziale und psychische Gesundheitsoutcomes, Resilienz
 - Interventionsgruppe: wahrgenommene Einschränkungen in Lebensstilbereichen, Motivation
2. **Hygiene- und Schutzprotokoll** zur persönlichen Testung bei zulässigem Infektionsgeschehen und Testräume in Studienzentren
3. **Telefonische Kontakte** zur Stärkung der Adhärenz (booster-Sessions) bei Interviewpausierungen

AgeWell-Studie – Teil einer weltweiten Community

STUDY PROTOCOL

Open Access

AgeWell.de – study protocol of a pragmatic multi-center cluster-randomized controlled prevention trial against cognitive decline in older primary care patients



Andrea Zülke^{1†}, Tobias Luck^{1,2†}, Alexander Pabst¹, Wolfgang Hoffmann^{3,4}, Jochen René Thyrian⁴, Jochen Gensichen⁵, Hanna Kaduszkiewicz⁶, Hans-Helmut König⁷, Walter E. Haefeli⁸, David Czock⁸, Birgitt Wiese⁹, Thomas Frese¹⁰, Susanne Röhr^{1†} and Steffi G. Riedel-Heller^{1†}

Abstract

Background: In the absence of treatment options, the WHO emphasizes the identification of effective strategies as a key element to counteract the dementia epidemic. Regarding the complex nature of dementia, simultaneously targeting multiple risk factors should be particularly effective for prevention. So far, few such multi-component trials have been launched, but yielding promising results. In Germany, such initiatives are lacking, and translation of these complex interventions into routine care was not yet achieved. *AgeWell.de* will be conducted as the first multi-component prevention trial in Germany which is in the primary care setting.


Methods: *AgeWell.de* will be designed as a multi-centric, cluster-randomized controlled multi-component trial. Participants will be older community-dwelling general practitioner (GP) patients (60–77 years; $n = 1000$) with increased dementia risk according to CAIDE (Cardiovascular Risk Factors, Aging, and Incidence of Dementia) Risk Score. Recruitment will take place at 5 study sites across Germany. GP practices will be randomized to intervention A (advanced) or B (basic). GPs will be blinded to their respective group assignment, as will be the patients. The multi-component intervention (A) includes nutritional counseling, cognitive training, optimization of medication, management of vascular risk factors, social activity, and specific interventions targeting grief and depression. Intervention B includes general health advice on components and GP treatment as usual. We hypothesize that over the 2-year follow-up period the intervention will benefit significantly from the intervention program in terms of preserved cognitive function/delay in cognitive decline (primary outcome), and other relevant (secondary) outcomes (e.g. quality of life, social activities, depressive symptoms, cost-effectiveness).

(Continued on next page)



Developed by the FINGERS Brain Health Institute. Created with mapchart.net

Impact der COVID-19-Pandemie international



Kollaborative WW-FINGERS-Publikation zum Impact der COVID-19-Pandemie auf das statistische Design und Analysepläne für Multikomponenten-Interventionstudien

- Erfahrungen und Erkenntnisse federführend von AgeWell.de (D), mit J-MINT (Japan) und U.S.Pointer (USA)
- Einblicke und Ableitungen von Empfehlungen für vergleichbare Studien und geplante Studien

Publikation am 11.03.21

Röhr et al. in
Alzheimer's & Dementia: Translational
Research & Clinical Interventions (TRCI)



Implikationen / Schlussfolgerungen

- Umfangreiche Maßnahmen zur **Anpassung** der Studie an Pandemielage
- **Zusätzliche Datenerhebung** zur Einordnung des Pandemie-Impacts und Abgleich mit der Allgemeinbevölkerung (siehe Exkurs)
- **Kontinuierlicher internationaler Austausch** mit internationaler Wissenschafts-Community zur Entwicklung von Adaptionstrategien
- **Unausweichliche Verzögerungen** in den geplanten Nachbefragungen durch Dynamik des Infektionsgeschehens; zieht Projektverlängerung nach sich....



Exkurs I: Abgleich der Survey-Daten aus AgeWell.de mit repräsentativer Studie in der Altenbevölkerung

Work in Progress:

Abgleich der Survey-Daten aus AgeWell.de mit repräsentativer Studie in der Altenbevölkerung (n = 1005, Alter > 65 Jahre) mit identischen Messinstrumenten

RESEARCH ARTICLE

Open Access

Mental wellbeing in the German old age population largely unaltered during COVID-19 lockdown: results of a representative survey



Susanne Röhr^{1,2*}, Ulrich Reininghaus^{3,4,5} and Steffi G. Riedel-Heller¹

Abstract

Background: Older individuals are at increased risk of a severe and lethal course of COVID-19. They have typically been advised to practice particularly restrictive social distancing ('cocooning'), which has sparked much debate on the consequences for their mental wellbeing. We aimed to provide evidence by conducting a representative survey among the German old population during COVID-19 lockdown.

Methods: A computer-assisted standardized telephone interview was conducted in a randomly selected and representative sample of the German old age population (n = 1005; age ≥ 65 years) during the first lockdown in April 2020. Assessments included sociodemographic factors, aspects of the personal life situation during lockdown, attitudes towards COVID-19, and standardized screening measures on depression, anxiety, somatization, overall psychological distress (Brief Symptom Inventory/BSI-18) and loneliness (UCLA 3-item loneliness scale). Sampling-weighted descriptive statistics and multiple multivariable regression analyses were conducted.


Results: Participants were M = 75.5 (SD = 7.1) years old; 56.3% were women. At data collection, COVID-19 lockdown had been in force for M = 28.0 (SD = 4.8) days. Overall, older individuals were worried about COVID-19, but supportive of the lockdown. Mean BSI-18 scores were 1.4 for depression, 1.6 for anxiety and 2.2 for somatization as well as 5.1 for global psychological distress. These figures did not indicate worse mental wellbeing, given normative values established by studies before the pandemic (2.0, 1.6, 2.4, 6.0, respectively). The prevalence of loneliness was 13.1%, which also fell within a range of estimates reported by studies before the pandemic. There were only few significant associations of aspects of the personal life situation during lockdown and attitudes towards COVID-19 with mental wellbeing. Resilience explained a large amount of variance.

(Continued on next page)


Exkurs II: Repräsentativerhebung im 1. Lockdown: Einstellungen

- Teilnehmer: $n=1005$, mittleres Alter $M=75.5$ ($SD=7.1$) Jahre, 56.3% Frauen
- COVID-19-Lockdown war in Kraft für $M=28.0$ ($SD=4.8$) Tage
- Ältere Menschen waren besorgt über COVID-19, befürworteten jedoch Lockdown


Sorgen aufgrund von Covid-19



Unterstützung der Regierungsmaßnahmen



Exkurs III: Repräsentativerhebung im 1. Lockdown: Psychische Gesundheit



¹ Petrowski K, Schmalbach B, Jagla M, Franke GH, Brähler E. Norm values and psychometric properties of the brief symptom inventory-18 regarding individuals between the ages of 60 and 95. BMC Med Res Methodol. 2018;18(1):164.

² Röhr, S., Reininghaus, U., & Riedel-Heller, S. (2020, July 15). Mental and social health in the German old age population largely unaltered during COVID-19 lockdown: results of a representative survey. PrePrint: <https://doi.org/10.31234/osf.io/7n2bm>



AgeWell.de

Danke für Ihre Aufmerksamkeit

Prof. Dr. med. Steffi G. Riedel-Heller, MPH
PD Dr. Melanie Luppä, Dr. Susanne Röhr
& die AgeWell.de-Studienzentrenleiter